Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review

Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Husnain, Muhammad, Kurtin, Sandra, Barkett, Nikki, Riaz, Irbaz Bin, Agarwal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056304/
https://www.ncbi.nlm.nih.gov/pubmed/27752376
http://dx.doi.org/10.1155/2016/2490168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056304/
https://www.ncbi.nlm.nih.gov/pubmed/27752376
http://dx.doi.org/10.1155/2016/2490168

Ejemplares similares